However, clinical consideration is still required
Retatrutide is being studied in metabolic, adipose, and hepatic research models
They can help rule out other conditions, such as gastroesophageal reflux disease (GERD), suggest a change to your Wegovy dosing schedule , or recommend a different treatment
Mounjaro comes with years of post-marketing surveillance data confirming its safety in millions of real-world patients
It belongs to a class of medications called glucose-like peptide 1 (GLP-1) receptor agonists
In addition to weight reduction, the Phase 2 trial reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in blood pressure Favourable changes in lipid profiles Reductions in fasting glucose and insulin resistance Increases in heart rate were also observed, consistent with findings seen with other incretin-based therapies These findings suggest that retatrutide may offer broader metabolic benefits beyond weight loss alone, which is particularly relevant for patients with obesity-related comorbidities such as type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), or elevated cardiovascular risk
.png)
